Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR: Fluorescence-guided surgery in laryngeal and hypopharyngeal cancer
2020-003474-45Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Nov 2021
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cRGD-ZW800-1 in laryngeal squamous cell carcinoma (LSCC) and squamous cell carcinoma of the hypopharynx, sponsored by Erasmus MC. Primary endpoint: Intraoperative tumor-to-background ratio of cRGD-ZW800-1. Started Nov 2021; status: active.
02
Drugs
cRGD-ZW800-1
03
Conditions
laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on 2020-003474-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003474-45.